EXAGEN INC. (XGN): Price and Financial Metrics


EXAGEN INC. (XGN)

Today's Latest Price: $16.13 USD

0.14 (0.88%)

Updated Jan 26 4:00pm

Add XGN to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 64 in Medical - Diagnostics/Research

See all "A" rated Strong Buy stocks

XGN Stock Summary

  • With a one year PEG ratio of 0.62, Exagen Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than just 6.06% of US stocks.
  • XGN's went public 1.36 years ago, making it older than just 1.22% of listed US stocks we're tracking.
  • Of note is the ratio of Exagen Inc's sales and general administrative expense to its total operating expenses; 77.03% of US stocks have a lower such ratio.
  • If you're looking for stocks that are quantitatively similar to Exagen Inc, a group of peers worth examining would be KIDS, SREV, TELA, ARTW, and HAYN.
  • Visit XGN's SEC page to see the company's official filings. To visit the company's web site, go to avisetest.com.

XGN Stock Price Chart Interactive Chart >

Price chart for XGN

XGN Price/Volume Stats

Current price $16.13 52-week high $24.98
Prev. close $15.99 52-week low $10.29
Day low $15.41 Volume 13,100
Day high $16.39 Avg. volume 38,394
50-day MA $14.37 Dividend yield N/A
200-day MA $13.67 Market Cap 204.08M

EXAGEN INC. (XGN) Company Bio


Exagen, Inc. is a commercial-stage diagnostics company. It engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. The company operates under the Avise brand.


XGN Latest News Stream


Event/Time News Detail
Loading, please wait...

XGN Latest Social Stream


Loading social stream, please wait...

View Full XGN Social Stream

Latest XGN News From Around the Web

Below are the latest news stories about Exagen Inc that investors may wish to consider to help them evaluate XGN as an investment opportunity.

The Daily Biotech Pulse: Fluidigm's Saliva-Based COVID Test Approved In Europe, China Backs Amarin's Vascepa

Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 21) * Acasti Pharma Inc (NASDAQ: ACST) * Alimera Sciences Inc(NASDAQ: ALIM) * argenx SE - ADR (NASDAQ: ARGX) * Axonics Modulation Technologies Inc (NASDAQ: AXNX) * AzurRx BioPharma Inc (NASDAQ: AZRX) * Chimerix Inc (NASDAQ: CMRX) * Edap Tms SA(NASDAQ: EDAP) * Eli Lilly And Co (NYSE: LLY) (announced positive results for its COVID-19 antibody treatment) * ESSA Pharma Inc (NASDAQ: EPIX) * Idera Pharmaceuticals Inc (NASDAQ: IDRA) * Inari Medical Inc (NASDAQ: NARI) * INmune Bio Inc (NASDAQ: INMB) (INSM) * Integra Lifesciences Holdings Corp (NASDAQ: IART) * Inventiva ADR Representing Ord Shs (NASDAQ: IVA) * Jounce Therapeutics Inc(NASDAQ:...

Yahoo | January 22, 2021

Exagen Inc. Partners with Boston’s Tufts Medical Center to Offer AVISE® Testing as an In-Network Benefit for Patients Suffering from Debilitating Autoimmune Diseases

SAN DIEGO, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today that all AVISE test offerings (CTD, Lupus, SLE Prognostic, SLE Monitor, APS, Vasculitis AAV, MTX, and HCQ) are now a contracted in-network service with Tufts Medical Center, an internationally-respected academic medical center. “Autoimmune diseases are challenging for healthcare providers to diagnose and treat and can have serious implications for patients. We needed to provide a more accurate testing option and expanded access to testing to most effectively care for patients with autoimmune diseases in our Center for Arthritis and Rheumatic Diseases,” said John Butz, Director of Laboratory S...

Yahoo | January 21, 2021

Exagen issues preliminary testing revenue ahead of ICT chat

Exagen (XGN) moves up 1.98% after the autoimmune-related healthcare services company posts preliminary figures for FQ4 yesterday. Testing revenue to be $10.5-$10.8M (+10% to +13% Y/Y).However, the company holds back its SIMPONI revenue estimate due to the nature of syndicated pharmaceutical data reporting timing.Consensus: Analysts expect Exagen's total revenue to amount $10.10M (-1.12% Y/Y) and Non-GAAP...

Seeking Alpha | January 11, 2021

Exagen Inc. To Participate in 2021 ICR Conference

SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today that company management will participate in the 2021 ICR Conference, which takes place January 11-14, 2021. Ron Rocca, Exagen’s President and Chief Executive Officer, and Kamal Adawi, Exagen’s Chief Financial Officer, will participate in a virtual fireside chat on Thursday, January 14 at 11:30 AM ET, which is accessible to conference attendees. Management will also be participating in one-on-one meetings with investors during the event; meetings can be requested through the ICR Conference site. About Exagen Inc.Exagen is dedicated to transforming the care continuum for patients suffering fro...

Yahoo | January 5, 2021

Exagen Inc. Partners with Oregon’s St. Charles Health System to Offer AVISE® Testing as an In-Network Benefit for Patients Suffering from Debilitating Autoimmune Diseases

SAN DIEGO, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today that all AVISE test offerings (CTD, Lupus, SLE Prognostic, SLE Monitor, APS, Vasculitis AAV, MTX, and HCQ) are a contracted in-network service with St. Charles Health System, the largest provider of medical care in Central Oregon. “St. Charles has a far-reaching impact on the health and wellbeing of the communities they serve. As the largest employer in the region, providing access to AVISE testing will play an important part in enabling rheumatologists to improve patient care through the differential diagnosis, prognosis and monitoring of complex autoimmune diseases, including SLE,” said Ron...

Yahoo | January 4, 2021

Read More 'XGN' Stories Here

XGN Price Returns

1-mo 33.53%
3-mo 11.32%
6-mo 29.56%
1-year -29.73%
3-year N/A
5-year N/A
YTD 22.20%
2020 -48.03%
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8027 seconds.